Simple Summary Gastric cancer (GC) is one of the most common cancers and the third
leading cause of cancer deaths worldwide, with a high frequency of recurrence and …

Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and
cancer-related death. Claudin-18.2 (CLDN18. 2), a transmembrane protein, is a major …

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …

Background Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.
2), has shown efficacy in patients with CLDN18. 2-positive, human epidermal growth factor …

Background We conducted comprehensive clinical and molecular characterization of
claudin 18.2 expression (CLDN18. 2) in advanced gastric or gastroesophageal junction …

Claudins are a tetraspan membrane protein multigene family that plays a structural and
functional role in constructing tight junctions. Claudins perform crucial roles in maintaining …

Background The investigational use of zolbetuximab (IMAB362), a groundbreaking
monoclonal antibody medication targeting claudin 18.2 (CLDN18. 2), for treatment of …

Gastric cancer (GC) is one of the most common malignancies worldwide. The histology-and
morphology-based Lauren classification of GC has been widely used for over 50 years in …

Gastric cancer is a heterogeneous disease with diverse histological and genomic subtypes,
making it difficult to demonstrate treatment efficacy in clinical trials. However, recent efforts …

Abstract Claudin 18.2, a tight-junction molecule predominantly found in the nonmalignant
gastric epithelium, becomes accessible on the tumour cell surface during malignant …